Synapse Open Synapse
Biology

PepGen soars on promising early data for muscular dystrophy drug

BioPharma Dive · · 2 min read

While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.

Latest from BioPharma Dive